By proceeding, you agree to our Terms of Use and Privacy Policy.
Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
23-25 May 2022
CHI’s Sixth Annual Immuno-Oncology Summit Europe returns to London’s Canary Wharf for three packed days of science and technology, discussion and networking, with coverage of recent advances in the development of promising immuno-oncology treatments.
Event Ended
Hybrid
Paid
London